Physician profile
Madankumar Raj
NPI 1528029162
$4,298.04
in general payments reported to CMS, 2019-2025
27 companies · $724 in 2025
The $724 reported for 2025 was more than what a typical Pain Medicine provider received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $423 · 2020: $20.66 · 2021: $938 · 2022: $810 · 2023: $874 · 2024: $507 · 2025: $724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,105.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $1,216.06 | 2019-2025 | Xtampza, Belbuca |
| Boston Scientific Corporation | $459.64 | 2019-2025 | General - Pain Management |
| Kowa Pharmaceuticals America, INC. | $457.12 | 2022-2023 | Seglentis |
| Scilex Pharmaceuticals INC. | $378.95 | 2021-2025 | Ztlido |
| Nevro Corp. | $260.68 | 2019-2021 | |
| Allergan, INC. | $259.38 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $221.02 | 2021-2025 | Relistor |
| Abbvie INC. | $155.18 | 2022-2025 | |
| Grt US Holding, INC. | $118.00 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $100.51 | 2025 | |
| Pfizer INC. | $65.70 | 2020-2021 | |
| Abbott Laboratories | $57.47 | 2021 | |
| Forte Bio-Pharma LLC | $54.56 | 2023-2025 | Prolate, Nalocet, Tanlor |
| Bioventus LLC | $51.31 | 2022-2024 | Supartz Fx Sodium Hyaluronate |
| Saluda Medical Americas, INC. | $50.85 | 2025 | Evoke |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nalu Medical, INC. | $50.64 | 2021 | |
| Valinor Pharma, LLC | $46.83 | 2024-2025 | Movantik |
| Medtronic, INC. | $46.15 | 2024 | Intellis Adaptivestim |
| Almatica Pharma LLC | $44.14 | 2022-2023 | Gralise |
| Depuy Synthes Sales INC. | $41.31 | 2024-2025 | Monovisc, Orthovisc |
| Hikma Pharmaceuticals USA | $40.56 | 2021-2024 | Kloxxado |
| Biohaven Pharmaceutical Holding Company LTD. | $24.58 | 2022 | |
| Sanofi-Aventis U.S. LLC | $24.37 | 2022 | |
| Djo, LLC | $23.87 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $18.34 | 2025 | Dysport |
| Zimmer Biomet Holdings, INC. | $15.62 | 2019 | |
| Arbor Pharmaceuticals, INC. | $15.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madankumar Raj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.